Advertisement
Astra Zeneca
Subscribe to Astra Zeneca

The Lead

AstraZeneca, MD Anderson Enter Collaboration to Help Improve Patient Outcomes in Ovarian/ Gynecologic Cancers

January 29, 2015 1:06 pm | News | Comments

AstraZeneca and The University of Texas MD Anderson Cancer Center today announced a multi-year, strategic research collaboration to conduct multiple, parallel clinical and clinically-related studies in ovarian and other gynecologic cancers with the aim of improving patient outcomes.

AstraZeneca’s BRILINTA® Meets Primary Endpoint in Both 60mg and 90mg Doses

January 14, 2015 8:19 am | News | Comments

The study assessed BRILINTA® (ticagrelor) tablets at either 60mg twice daily or 90mg twice daily...

MedImmune Enters Licensing Agreement with Omnis Pharmaceuticals for Oncolytic Viruses in Immuno-Oncology

January 12, 2015 8:43 am | News | Comments

This agreement will allow MedImmune to combine key agents from its investigational immunotherapy...

AstraZeneca Cancer Drug, Companion Test Approved

December 22, 2014 8:28 am | by LINDA A. JOHNSON, AP Business Writer | News | Comments

The FDA granted accelerated approval to the first in a new class of targeted drugs for ovarian...

View Sample

FREE Email Newsletter

European Commission Approves Lynparza™ for Advanced BRCA-Mutated Ovarian cancer

December 18, 2014 9:04 am | News | Comments

AstraZeneca today announced that the European Commission has granted Marketing Authorization for Lynparza™ capsules as the first therapy for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cance.

GlobalData: Patent Cliff Means Pharmaceutical Companies Will Lose $65B by 2019

December 10, 2014 9:24 am | News | Comments

Pharmaceutical companies will suffer an estimated $65B drop in sales by 2019 due to the patent expiries of several leading drugs, according to research and consulting firm GlobalData. The company’s report states that the drug makers hit hardest will include Otsuka, Eli Lilly, and AstraZeneca, with a significant proportion of losses coming in the Central Nervous System treatment sector.

Dynavax and AstraZeneca to Move Asthma Treatment Into Phase 2a Clinical Study

December 8, 2014 8:18 am | News | Comments

Dynavax Technologies and AstraZeneca signed an amendment to the existing Research Collaboration and License Agreement under which AstraZeneca will fully fund and Dynavax will conduct a Phase 2a safety and efficacy trial of AZD1419 in patients with asthma.

Advertisement

FDA Accepts New Drug Application for IRESSA

December 2, 2014 8:09 am | News | Comments

AstraZeneca today announced that the FDA has accepted for filing the NDA for IRESSA® (gefitinib) as a targeted monotherapy for the first line treatment of patients with advanced or metastatic epidermal growth factor receptor mutation positive (EGFRm) non-small cell lung cancer (NSCLC).

Eli Lilly and AstraZeneca Start Pivotal Clinical Trial for Patients with Early Alzheimer's Disease

December 1, 2014 8:22 am | News | Comments

Eli Lilly and and AstraZeneca today announced enrollment of the first patient into AMARANTH, a Phase II/III study of an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer's disease.

AstraZeneca to Expand Frederick, MA Biologics Manufacturing Center

November 24, 2014 8:46 am | News | Comments

AstraZeneca has announced plans to expand its biologics manufacturing center in Frederick, Md. The more than $200M project will increase production capacity at the facility to support AstraZeneca’s maturing pipeline, and will help position the company to keep pace with a growing demand for the development and use of biologics, which currently represent nearly 50% of AstraZeneca’s overall pipeline.

AstraZeneca and Isis Pharmaceuticals to Co-Develop Targeted Oligonucleotide Delivery Methods

November 13, 2014 8:23 am | News | Comments

Isis Pharmaceuticals and AstraZeneca today announced a strategic alliance to discover and develop novel delivery methods for antisense oligonucleotides. The new delivery approaches seek to target the desired tissue more effectively. The agreement builds on an existing collaboration between AstraZeneca and Isis Pharmaceuticals.

AstraZeneca Initiates Development Program for BRILINTA Reversal Agent

November 13, 2014 8:06 am | News | Comments

AstraZeneca has begun a pre-clinical development program to evaluate the ability of investigational antibody, MEDI2452, to rapidly and specifically reverse the antiplatelet effects of ticagrelor in rare emergency situations such as urgent surgery, or in the event of major bleeding.

Advertisement

Amgen and AstraZeneca Announce Brodalumab Phase III Results

November 12, 2014 9:01 am | News | Comments

AstraZeneca and Amgen today announced that AMAGINE-3TM, a pivotal, multi-arm Phase III trial evaluating two doses of brodalumab in more than 1,800 patients with moderate-to-severe plaque psoriasis, met its primary endpoints when compared with both Stelara® (ustekinumab) and placebo at week 12

AstraZeneca to Divest Myalept to Aegerion

November 6, 2014 10:44 am | News | Comments

AstraZeneca has entered into a definitive agreement with Aegerion Pharmaceuticals, Inc. to divest Myalept™ (metreleptin for injection), an orphan product that is indicated to treat complications of leptin deficiency in patients with generalized lipodystrophy.

Isis Pharmaceuticals Earns $7.5M Milestone Payment from AstraZeneca

November 6, 2014 8:52 am | News | Comments

Isis Pharmaceuticals has earned a $7.5 million milestone payment, the first of two milestone payments totaling $15 million, from AstraZeneca for the advancement of ISIS-STAT3Rx, also referred to as AZD9150, in patients with advanced cancers.  

AstraZeneca And Pharmacyclics Enter Clinical Trial Collaboration to Evaluate IMBRUVICA In Hematologic Cancers

November 4, 2014 6:09 pm | News | Comments

AstraZeneca and Pharmacyclics announced that they have entered into a clinical trial collaboration to evaluate novel combination therapies targeting a number of hematologic cancers.            

FDA Approves Once-Daily XIGDUO™ XR Tablets for Adults with Type 2 Diabetes

October 30, 2014 8:04 am | News | Comments

AstraZeneca today announced that the FDA has approved once-daily XIGDUO™ XR (dapagliflozin and metformin hydrochloride extended-release) for the treatment of adults with type 2 diabetes.               

Advertisement

Off-Label Prescribing of Antipsychotic Drug Highlights Lack of Oversight

October 22, 2014 8:38 am | by Adam Miller, The Canadian Press | News | Comments

An increase in the number of prescriptions of a powerful antipsychotic drug for conditions not approved by Health Canada is raising concern about what medical experts call lack of professional and government oversight of doctors' prescribing practices.

MedImmune Receives FDA Fast Track Designation for Development of MEDI3902 for Prevention of Nosocomial Pneumonia

September 23, 2014 8:22 am | News | Comments

AstraZeneca announced today that its global biologics research and development arm, MedImmune, has received fast track designation from the FDA for its investigational monoclonal antibody (mAb) MEDI3902 for the prevention of nosocomial pneumonia caused by Pseudomonas aeruginosa (P. aeruginosa), a highly drug-resistant bacterial pathogen.

AstraZeneca and Lilly to Develop and Commercialize Alzheimer’s Disease Treatment

September 16, 2014 8:39 am | News | Comments

AstraZeneca and Eli Lilly announced an agreement to jointly develop and commercialize AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer’s disease.  

AstraZeneca and Redx Pharma to Collaborate on Targeting Genetic Drivers of Tumor Growth

September 3, 2014 8:54 am | News | Comments

AstraZeneca has entered into a research collaboration with Redx Pharma Limited to discover and develop new molecules targeting a genetic driver of tumor growth and survival. The research will complement AstraZeneca’s strategic approach focused on genetic drivers of cancer and mechanisms of resistance to established and novel cancer therapies.

UK High Court Gives Positive Judgment in Teva's Patent Case Against AstraZeneca

September 3, 2014 8:33 am | News | Comments

Teva Pharmaceutical announced that a positive judgment has been given by the UK High Court in support of Teva's case against AstraZeneca relating to the validity of EP 1,085,877 covering the SMART ( S ingle inhaler M aintenance A nd R eliever T herapy) indication for AstraZeneca's fixed dose formoterol/budesonide combination product, Symbicort®.

DOJ Closes Probe Into AstraZeneca Trial

August 19, 2014 4:37 pm | by Associated Press | News | Comments

British drugmaker AstraZeneca says the U.S. Department of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action.                

AstraZeneca Advances Tralokinumab for Severe Asthma to Phase III

August 14, 2014 8:32 am | News | Comments

AstraZeneca announced the start of the Phase III program for tralokinumab, a potential treatment for patients with severe, inadequately controlled asthma, developed by MedImmune, the company’s global biologics research and development arm.  

AstraZeneca Announces Results of Phase III Gout Treatment Trial

August 13, 2014 8:46 am | News | Comments

AstraZeneca today announced positive top-line results from CLEAR1, CLEAR2 and CRYSTAL, the pivotal Phase III clinical trials investigating the potential of lesinurad, a selective uric acid re-absorption inhibitor (SURI), as a combination therapy for the treatment of patients with symptomatic gout.

AstraZeneca and Kyowa Hakko Kirin Partner on Immuno-Oncology Clinical Study

July 30, 2014 10:02 am | News | Comments

AstraZeneca today announced that it has entered into a clinical study collaboration with Kyowa Hakko Kirin for a Phase I/Ib immuno-oncology study that will evaluate the safety and efficacy of two separate combinations of three investigational compounds in multiple solid tumours.

AstraZeneca to Acquire Almirall's Respiratory Disease Business

July 30, 2014 8:11 am | News | Comments

AstraZeneca today announced that it has entered an agreement to transfer to the company the rights to Almirall’s respiratory franchise for an initial consideration of $875 million on completion, and up to $1.22 billion in development, launch, and sales-related milestones.

AstraZeneca and QIAGEN to Develop Diagnostic Test for Lung Cancer Patients Suitable for Treatment with IRESSA

July 28, 2014 8:49 am | News | Comments

AstraZeneca today announced that it has entered into a collaboration with Netherlands-based QIAGEN to develop a non-invasive diagnostic test to identify non-small cell lung cancer (NSCLC) patients who are suitable for treatment with IRESSA®.  

AstraZeneca and Roche to Develop Companion Diagnostic Test for AZD9291

July 28, 2014 7:57 am | News | Comments

AstraZeneca today announced it has entered into collaboration with Roche to develop a plasma-based companion diagnostic test to support AZD9291, AstraZeneca’s investigational compound in clinical development for non-small-cell lung cancer (NSCLC).

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading